Aquestive Therapeutics opened lower at $3.56, compared with its previous close of $3.58. In the last trading session, the stock traded between $3.45 and $3.68. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Aquestive Therapeutics is now worth
$ 58.15
Resulting in a loss of
$ 41.85 (41.85%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.00 (-0.11%)
Day High
$3.68
Day Low
$3.45
Day Open
$3.56
Prev Close
$3.58
Volume
23,95,162
1W Return
-5.52%
1M Return
-25.75%
3M Return
-18.84%
6M Return
-17.60%
1Y Return
-37.15%
Market Cap ($ Mn)
449
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-72.82%
EPS (TTM)
$-0.13
1 Week
-5.52%
1 Month
-25.75%
3 Months
-18.84%
6 Months
-17.60%
9 Months
-6.39%
FDA accepts Aquestive's Anaphylm NDA, sets March 2027 decision date
FDA accepted Anaphylm NDA resubmission as complete with Class 2 classification. PDUFA goal action date set for March 16, 2027. Resubmission addressed January 2026 Complete Response Letter using August 2026 study data. Canadian New Drug Submission planned for Q4 2026.
28 days agoAquestive Therapeutics resubmits FDA application for Anaphylm allergy treatment
Aquestive Therapeutics resubmitted its FDA application for Anaphylm after addressing a Jan. 30, 2026 Complete Response Letter. The company completed a confirmatory pharmacokinetic trial and a human factors study with modified packaging. The self-administration cohort in the trial experienced no protocol-defined use errors. Anaphylm is a sublingual epinephrine prodrug film that dissolves immediately in the mouth. Shares fell 1.04% to $4.97 in premarket trading following the announcement.
1mo agoAquestive Therapeutics to present at four September investor conferences
Management to speak at four investor conferences in September 2026. Fireside chat scheduled at Cantor Healthcare Conference on September 9. Presentation set for H.C. Wainwright conference on September 14. Webcasts of key sessions will be available for 30 days post-event.
2mo agoAquestive Q2 Results: Revenue rises 38% to $13.8 million
Aquestive Therapeutics reported Q2 2026 revenue of $13.8 million, a 38% increase year-over-year, driven by higher manufacturing volumes. The company recorded a GAAP net loss of $22.9 million, heavily influenced by an $11.7 million one-time debt extinguishment loss; adjusted net loss was $11.2 million. Regulatory milestones were met for Anaphylm, with an NDA resubmission targeted for Q3 2026.
3mo agoAquestive Therapeutics Latest Results: Sales guidance affirmed at $46-50M
Aquestive Therapeutics maintains its FY2026 sales guidance of $46.000 million to $50.000 million. This range is below the $50.584 million estimate, indicating a conservative outlook for the fiscal year.
3mo agoAquestive advances Anaphylm FDA resubmission after positive study results
Aquestive Therapeutics Inc. reported positive human factors and pharmacokinetic study results for its Anaphylm sublingual film, addressing prior FDA concerns regarding packaging and administration errors. The company plans to resubmit its New Drug Application in Q3 2026 while advancing global regulatory filings. Shares rose 13.45% on the news.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Aquestive Therapeutics is now worth
$ 58.15
Resulting in a loss of
$ 41.85 (41.85%)
Note: Past profits do not guarantee future returns.
